Areas of Focus


Expanding our research focus through a collaboration with Regeneron, we are targeting unmet needs in immune diseases including atopic dermatitis, rheumatoid arthritis, asthma, and nasal polyposis, and eosinophilic esophagitis.

Immunology is an area of growth for Sanofi Genzyme and an area in which we hope to make a significant difference in patients’ lives. In collaboration with Regeneron, we currently have two therapies on the market and are researching and developing several new therapeutic areas.

The first therapy, which is approved in the U.S., is for adults with inadequately controlled moderate-to-severe atopic dermatitis, a chronic inflammatory skin disease and the most common form of eczema. A second therapy, which is approved in the U.S. and Canada, is for the treatment of adults with moderate to severe rheumatoid arthritis, a chronic and painful inflammatory disorder that damages the joints.

We are also studying other allergic and respiratory diseases, including asthma, and nasal polyposis, and eosinophilic esophagitis.

Our Inspiration
Last Updated: 5/22/2017
Contact Us
Genzyme Corporation

500 Kendall Street
Cambridge, MA 02142
T: 617-252-7500
F: 617-252-7600

Send Email
Atopic Dermatitis: From Education to Empowerment

Understand AD is a national awareness campaign focused on educating people about moderate-to-severe atopic dermatitis (AD), a chronic form of eczema that can be serious. By educating Americans about the physical and quality of life impact of atopic dermatitis, Understand AD will give a voice to and empower the people living with the disease.